Status:
NOT_YET_RECRUITING
SNAPS Breast Cancer Patient Study Breast Cancer Patients
Lead Sponsor:
Immunis.AI
Collaborating Sponsors:
Duke University
Conditions:
Breast Cancer
Breast Cancer Female
Eligibility:
FEMALE
18+ years
Brief Summary
Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large ...
Detailed Description
Efficient next generation RNA sequencing platforms have allowed for whole genome expression profiling of individual populations of immune cells as a novel means of searching for patterns of gene expre...
Eligibility Criteria
Inclusion
- Patients \> 18 yrs of age.
- Patients diagnosed with stage I-IV breast cancer, who have not begun definitive therapy.
- Patients undergoing screening mammograms for breast cancer.
Exclusion
- Patients with a history of a different cancer within the previous 3 years (except non melanoma skin cancer).
- Any prior treatment (surgery, chemo, hormonal, radiation, biologics, etc.) for current cancer.
- Any biopsy which resulted in the entire tumor tissue being removed.
- History of previous breast cancer.
- Patients unable to provide informed consent.
- Patients with an abnormal screening mammogram.
- Patients whose hormone receptor and/or HER2 status are not available.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05370300
Start Date
September 1 2025
End Date
December 31 2027
Last Update
March 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University
Durham, North Carolina, United States, 27710